Overview
Vosoritide (brand name Voxzogo) is a modified analogue of C-type natriuretic peptide (CNP) developed by BioMarin Pharmaceutical. It received FDA approval in November 2021 for children with achondroplasia aged 5 years and older with open epiphyses; the approval was extended in 2023 to children as young as 4 months. Achondroplasia is the most common form of disproportionate short stature, caused by activating mutations in FGFR3 that suppress chondrocyte proliferation at the cartilage growth plate.
Vosoritide binds the natriuretic peptide receptor B (NPR-B/NPR2) on growth-plate chondrocytes, activating particulate guanylyl cyclase and increasing intracellular cGMP. cGMP inhibits the MAPK arm of the overactive FGFR3 signaling pathway, restoring chondrocyte proliferation, extracellular matrix production, and endochondral ossification.
In the pivotal phase 3 trial, daily subcutaneous vosoritide increased mean annualized growth velocity by approximately 1.57 cm/year versus placebo over 52 weeks, with sustained benefit through extension studies. Long-term data suggest cumulative gains in height and improvements in body proportions, though final adult height data are still maturing.
Vosoritide is generally well tolerated. Transient injection-site reactions and mild, asymptomatic decreases in blood pressure are the most common adverse events. It is not indicated in children with closed epiphyses.
Quick facts
- Mechanism
- CNP analogue / NPR-B agonist that antagonizes FGFR3-MAPK signaling in growth-plate chondrocytes
- Primary use
- Achondroplasia in children with open growth plates
- Evidence
- strong
- FDA
- Approved
- Route
- Daily subcutaneous injection
- Typical results
- Increases annualized growth velocity by ~1.6 cm/year vs placebo in children with achondroplasia
Chemical information
Vosoritide (C₁₇₆H₂₉₀N₅₆O₅₁S₃) is a tissue remodeling compound with a molecular weight of 4102.78 g/mol. Its structural characteristics underpin its biological activity in tissue remodeling and structural repair.
How Vosoritide works
Vosoritide binds NPR-B on growth-plate chondrocytes, activating particulate guanylyl cyclase and increasing intracellular cGMP. cGMP activates PKG, which inhibits RAF1 phosphorylation and dampens MEK/ERK signaling downstream of the overactive FGFR3 receptor. The net effect is restoration of chondrocyte proliferation, hypertrophy, and matrix synthesis at the growth plate, increasing endochondral bone elongation.
Native CNP has a half-life of ~2 minutes due to rapid clearance by neutral endopeptidase and NPR-C. Vosoritide is a 39-amino-acid modified analogue with an N-terminal extension designed to resist NEP degradation while preserving NPR-B affinity, giving a clinically practical half-life for once-daily dosing.
The achondroplasia mutation (typically G380R in FGFR3) constitutively activates FGFR3 in chondrocytes, suppressing growth through RAS-MAPK signaling. CNP/cGMP/PKG signaling provides an opposing brake on MAPK, and pharmacologic NPR-B agonism partially normalizes this dysregulation without correcting the underlying mutation.
Because vosoritide acts at the growth plate, it has no effect once epiphyses have closed. It does not directly correct anatomical features such as foramen magnum stenosis, though long-term effects on these complications are under study.
- NPR-B agonism: Activates particulate guanylyl cyclase in growth-plate chondrocytes
- cGMP/PKG signaling: Inhibits RAF1 and downstream MAPK pathway
- Counters FGFR3 overactivity: Restores chondrocyte proliferation and matrix production
- Endochondral bone growth: Increases annualized growth velocity
- NEP-resistant analogue: Engineered for once-daily SC dosing
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Mass | ~4102 g/mol (39-amino-acid analogue) | Modified CNP designed for stability |
| Subcutaneous half-life | ~28 minutes | Short half-life is pharmacologically sufficient for growth-plate stimulation |
| Tmax (SC) | ~15 minutes | Rapid absorption after subcutaneous injection |
| Metabolism | Proteolytic degradation; renal clearance of fragments | No CYP involvement |
| Dosing | 15 µg/kg SC once daily (weight-based) | Approved pediatric dosing per FDA label |
Dosing & administration
Vosoritide dosing varies by indication and individual factors. Refer to the official prescribing information for approved indications.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Side effects & safety
Safety data for Vosoritide is established for approved indications via clinical trials. Long-term effects in humans remain incompletely characterized.
Common
- • Injection-site reactions (erythema, swelling, pain)
- • Transient decreases in blood pressure
- • Vomiting
- • Arthralgia
- • Fatigue
Serious / potential risks
- • Symptomatic hypotension (rare; mitigated by hydration and meals)
- • Effects on growth-plate dynamics with long-term use (under surveillance)
- • Hypersensitivity reactions (uncommon)
- • Unknown effects on adult height and skeletal complications (long-term studies ongoing)
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Antihypertensives | Additive blood pressure lowering | Monitor BP, especially with concomitant use |
| Growth hormone | Not formally studied in combination | Coordinate with pediatric endocrinology |
| NSAIDs | Potential modulation of natriuretic-peptide effects | Standard pediatric NSAID guidance |
| Vaccines | No known interaction | Routine pediatric vaccination is unaffected |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
Vosoritide is a tissue remodeling compound with research interest in achondroplasia, bone growth, cnp analog. While preclinical evidence is encouraging, it has received FDA approval for specific indications. Any use should be under qualified medical supervision.
Best for
- • Researchers studying tissue remodeling and structural repair
- • Individuals interested in achondroplasia under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Savarirayan R, Tofts L, Irving M, et al.. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3 trial. Lancet (2020). doi: 10.1016/S0140-6736(20)31541-5 PMID: 32891212
- [2] Savarirayan R, Irving M, Bacino CA, et al.. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med (2019). doi: 10.1056/NEJMoa1813446 PMID: 31269919
- [3] Lorget F, Kaci N, Peng J, et al.. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet (2012). doi: 10.1016/j.ajhg.2012.10.014 PMID: 23200862